A consistently greater incidence of MET amplifications has been extensively documented as a mechanism of acquired resistance in 5–22% EGFR-mutated NSCLC upon therapeutic pressure with EGFR-TKIs [105]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.